Especially midrange hormone receptor positive breast cancers may pose diagnostic challenges, as the indication for or against adjuvant chemotherapy cannot be met upon traditional clinic-pathological parameters in all instances [1–3]. The gene discussed is NR4A1; the disease is breast carcinoma.